(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 July 2008 (17.07.2008)

PCT

(10) International Publication Number
WO 2008/084410 A3

(51) International Patent Classification:
C07K 16/08 (2006.01) *A61K 39/42* (2006.01)
C12N 15/13 (2006.01) *A61P 31/22* (2006.01)

(21) International Application Number:
PCT/IB2008/001111

(22) International Filing Date: 3 January 2008 (03.01.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0700133.2 4 January 2007 (04.01.2007) GB

(71) Applicant *(for all designated States except US)*: **HUMABS LLC** [US/US]; 1700 Owens St., Suite 515, San Francisco, CA 94158 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LANZAVECCHIA, Antonio** [IT/CH]; Institute for Research in Biomedicine, Via Vincenzo Vela 6, CH-6500 Bellinzona (CH). **MACAGNO, Annalisa** [CH/CH]; Institute for Research in Biomedicine, Via Vincenzo Vela 6, CH-6500 Bellinzona (CH).

(74) Agents: **HALLYBONE, Huw, George** et al.; Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF



(57) Abstract: Neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The antibodies also have a high potency for the neutralisation of infection. Characterization of the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.

WO 2008/084410 A3

European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
24 December 2008